Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Prostate cancer disproportionately affects Black men; the reason for this phenomenon is unclear. The role of the health-care provider is important in screening for prostate cancer, advising on treatment and ensuring completeness of therapy. Cultural competency is necessary in health-care providers as, for most men in Europe, Australasia and the USA, the ethnicity and/or race of the urologist will be discordant with that of the patient.
Focus on quality of life after prostate cancer is vital to improve patient care. Improved assessment and proactive management of post-treatment functional outcomes is essential. Many aspects of the patients’ aftercare need to be improved in order to set up a clear path following prostatectomy. These improvements will enable a timely and efficient escalation of treatment and ameliorate patients’ survivorship experience.
Biomarkers that can improve risk stratification of patients with prostate cancer are urgently needed. In this Review, Khoo et al. outline mass spectrometry technologies that enable the systematic discovery and targeted validation of protein-based biomarkers in prostate-associated fluids.
Complications related to the use of mesh in pelvic floor reconstructive surgery are related to a number of factors. This Review discusses the foreign body response, the biomaterial properties of mesh, the patient-specific and surgical risk factors and the failings in mesh development, all of which have contributed to these complications.
Cancer recurrence after radical prostatectomy for high-risk prostate cancer is common. The addition of neoadjuvant hormonal therapy with the introduction of potent androgen receptor signalling inhibitors has gained interest in the oncological community. However, conclusions of a survival benefit with this therapy cannot currently be made and results of several phase II trials are much anticipated.
